Avalon GloboCare (NASDAQ:ALBT) Issues Earnings Results

Avalon GloboCare (NASDAQ:ALBT) announced its quarterly earnings results on Monday. The company reported ($0.49) EPS for the quarter, Zacks reports.

Avalon GloboCare Stock Performance

Shares of NASDAQ:ALBT opened at $0.40 on Tuesday. The firm’s 50 day moving average is $0.58 and its two-hundred day moving average is $1.04. The firm has a market capitalization of $3.33 million, a P/E ratio of -0.11 and a beta of -0.04. Avalon GloboCare has a 52 week low of $0.34 and a 52 week high of $4.74.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Avalon GloboCare in a report on Monday, April 20th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Avalon GloboCare Company Profile

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.